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A B S T R A C T
Juvenile myoclonic epilepsy is the most common form of idiopathic generalized epilepsy with onset at
puberty or late teenage years. About 80–90% of patients with juvenile myoclonic epilepsy respond to
appropriate antiepileptic treatment and achieve seizure freedom, and about 15% of patients become
intractable. Valproic acid, levetiracetam, lamotrigine, topiramate and zonisamide are used as ﬁrst line or
adjunctive therapy of this disorder. Lacosamide is approved for adjunctive treatment of partial onset
epilepsies. The role of lacosamide in treatment of idiopathic generalized epilepsy including juvenile
myoclonic epilepsy is unknown. We present three patients with classic clinical and electrographic
features of juvenile myoclonic epilepsy that were maintained on lacosamide (one on monotherapy and
two as adjuvant therapy). There were no special pharmacodynamic actions causing exacerbation or
worsening of myoclonic jerks or generalized seizures in these three patients. In conclusion, although, the
data from our three patients’ suggest that lacosamide may be effective in the treatment of juvenile
myoclonic epilepsy, larger studies are needed to explore efﬁcacy and role of lacosamide in the treatment
of this disorder.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Juvenile myoclonic epilepsy (JME) is a well deﬁned and distinct
clinical syndrome from other idiopathic generalized epilepsy (IGE)
syndromes.1 It is the most common form of IGE accounting for up
26% of patients with IGEs and up to 10% of patients with epilepsy.2
It is most likely to start at puberty or late teenage years.3 The
hallmark of the syndrome is myoclonic seizures, mainly involving
arms and upper body during post- awakening period.2,4 General-
ized tonic clonic seizures occur in most patients and are often
precipitated by sleep deprivation, stress, alcohol and hypoglyce-
mia.2,4 One third of the patients experience absence seizures.5
Electrographically, patients have a normal background with
interictal spike-wave and polyspike-wave discharges. Although
the repetition rate is usually higher than 3 Hz (most commonly
3.5–6 Hz), a variable range of 2–10 Hz have been reported.6 27–
41% of patients demonstrate photosensitivity.6
About 80–90% of patients with JME respond to appropriate
antiepileptic treatment and achieve seizure freedom,4 and about
15% of patients become intractable.7 The historical gold standard
for treatment of JME is valproic acid (VPA), which is considered the
most efﬁcacious drug for treatment of this disorder.8 However,* Corresponding author at: The University of Utah, 175N. Medical Drive East, 5th
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dependent side effects of tremor, alopecia, weight gain, and
secondary amenorrhea, or rare idiosyncratic reactions.9 Addition-
ally VPA has teratogenic effects with approximately three-fold
increase in the rate of major anomalies and it is best avoided when
possible.10,11 Therefore other antiepileptic medications (AEDs)
including levetiracetam (LEV), lamotrigine (LTG), topiramate
(TPM) and zonisamide (ZNS) have been used as ﬁrst line or as
add-on therapy.
JME requires lifelong treatment in most patients, as 90% of
patients will relapse if AEDs were withdrawn.12 This makes it
particularly important to select AEDs with good side effect proﬁle
in treatment of this disorder.
Lacosamide is a novel antiepileptic medication that has been
approved as adjunctive therapy for partial onset seizures since
September 2008 in Europe13 and since October 200814 in USA. It
was released as a Schedule V drug in June 2009.15 Lacosamide’s
unique mode of action involves its enhancement of the slow
inactivation of voltage-gated sodium channels without affecting
fast inactivation,16 which may be helpful in patients who are
intractable to or can not tolerate other AEDs.
There have been published abstracts reporting the use of
lacosamide as adjunctive treatment of idiopathic generalized
epilepsy.17,18 To our knowledge, there has been no journal
publications of case reports or case series about the role of
lacosamide in the treatment of IGE, including JME. Here we report
three patients with classical clinical and electrographic feature ofvier Ltd. All rights reserved.
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adjunctive therapy.
2. Cases
The following three cases were referred to the University of
Utah Comprehensive Epilepsy Clinic for evaluation and treatment
of their seizures.
Case 1 is a 19 year old right-handed lady with onset of
myoclonic jerks at 14 years of age shortly followed by develop-
ment of generalized tonic-clonic seizures. She was cognitively
normal and there was no reported history of learning disabilities.
Her inter-ictal EEG showed 4–6 Hz high amplitude polyspike and
slow waves and her MRI was normal. Her seizures have always
been easily controlled on VPA, but she complained of mental
slowing, mood and behavioral side effects on VPA. Therefore she
was tried on other antiepileptic medications. She experienced a
severe rash on LTG. She had anywhere from one to four seizures per
month on LEV up to a dosage of 6 g per day (serum level of 74).
When her TPM titration reached a dosage of 100 mg per day, she
experienced paresthesias and declined to stay on TPM, despite
counseling about the benign nature of paresthesias. She was then
started on lacosamide monotherapy and was titrated up to 400 mg
per day. She was seizure free on lacosamide monotherapy on
200 mg PO BID for 6 months, at which point despite extensive
counseling about the natural history of JME and lifelong necessity
for AED treatment, she decided to self discontinue her medication.
One week after self discontinuation she had four generalized tonic
clonic seizures in one day, following which she restarted her
medication, and she has now been seizure free for twelve months
on 400 mg/day of lacosamide and serum levels of 12–16. It is
presumed that the ﬂuctuation in her lacosamide level is due to
irregularities in her medication intake.
Case 2 is 19 year old left-handed/ambidextrous man with
seizure onset at age 15. He reported experiencing absence seizure,
myoclonic jerks and generalized tonic–clonic seizures. He was
cognitively normal and there was no reported history of learning
disabilities. He reported positive family history of primary
generalized epilepsy (syndromic classiﬁcation not known) in his
maternal cousin. His MRI was normal, and his interictal EEG
showed 3–4 Hz spike and slow waves as well as photoconvulsive
response. His seizure frequency (generalized tonic–clonic seizures)
was reported to be about one seizure every 6 weeks during periods
of mono-therapy, initially with LTG followed by VPA monotherapy.
At the time of his referral to epilepsy clinic he was on monotherapy
with the extended release formulation of VPA (with mildly supra
therapeutic serum level of 104) and was experiencing 1–2
breakthrough generalized seizures per year. He reported occa-
sional myoclonic jerks, mainly affecting his arms and shoulders.
During times of physical stress (playing hockey or exertion) he has
intermittent episodes of staring (lasting 5–10 s). He was unable to
report their true frequency. It was decided to add a second agent to
his antiepileptic regimen. He did not want to start ZNS or TPM due
to their cognitive side effects and he decided not to start LEV due to
its mood side effects. Lacosamide was added to his extended-
release VPA and was titrated up to 150 mg PO BID. He had no
generalized seizures for six months on dual therapy with
extended-release VPA and lacosamide 150 mg PO BID (with levels
of 9.2), but continued to experience occasional early AM myoclonic
jerks. His absences were shorter in duration (perceived by patient
to last a second or a fraction of a second). Therefore his lacosamide
was titrated up to 200 BID. This abated the myoclonic jerks and
absences. He has been seizure free for 18 months.
Case 3 is a 23-year old right handed lady with seizure onset at
age 15. Her ﬁrst seizure started with a prolonged period of
twitching that ended in a generalized tonic–clonic seizure.Retrospectively she had experienced isolated myoclonic jerks on
awakening, but she was not certain of when they started. Her MRI
was normal and her inter-ictal EEG showed diffuse poly-spike and
slow waves, as well as 2.5–4 Hz spike and slow waves. She was
started on VPA and became seizure free but experienced mood and
behavioral side effects. At age 17 she was changed to LTG and
maintained seizure freedom for two years. At age 19 during a
period of sleep deprivation, she experienced a single generalized
seizure on LTG. At age 20 she had a second break through seizure at
7th month of pregnancy. LEV at 500 mg PO BID was added to her
regimen, and she maintained seizure freedom throughout the rest
of her pregnancy, but experienced mood and behavioral side
effects. Postpartum, LEV was tapered and discontinued resulting in
another generalized seizure and therefore LEV 500 mg PO BID was
restarted again and her LTG was continued.
She was referred to epilepsy clinic in her postpartum period on
dual therapy with LEV and LTG. She was experiencing intermittent
myoclonic jerks and about one generalized seizure every 4–
6 weeks on this regimen. Patient had past medical history and
family history of kidney stones and therefore it was decided to
avoid TPM and ZNG. Lacosamide was added to her regimen and
titrated to 200 mg PO BID and her lamictal was tapered and
discontinued to avoid additive sodium channel blocking side
effects. She became seizure free on dual therapy with LEV and
lacosamide, but experienced side effects of fatigue, depression, and
anxiety. Therefore after four months of seizure freedom her
regimen was changed back to LTG 200 mg PO BID and higher
dosages of LEV (1000 mg PO BID). She maintained seizure freedom
on this regimen for another 4 months, but continued to experience
severe mood and behavioral side effects on levetiracetam. With her
newborn baby growing, she is able to sleep more continuous-hours
at night with less risk of sleep deprivation provoking seizures and
therefore the plan is to slowly taper her levetiracetam dosage with
eventual goal of return to LTG monotherapy.
3. Discussion
Valproic acid is historically considered the gold standard
medication for treatment of JME. More recently LEV, LTG, TPM,
ZNG have been used as ﬁrst line or adjunctive treatment.11,19–22 It
is well known that enzyme-inducing sodium channel blockers
(phenytoin, carbamazepine and oxcarbazepine) as well as vigaba-
trin and gabapentin can aggravate myoclonic seizures in JME.23–26
Lamotrigine, a non-enzyme inducing sodium channel blocker, can
also cause denovo myoclonus or aggravate existing myoclonic
seizures.27
The effects of lacosamide, a novel non-enzyme inducing sodium
channel blocker, on myoclonic seizures are not known. The use of
lacosamide as adjunctive treatment of intractable primary
generalized epilepsy has been reported in two published
abstract,17,18 one of which included patients with JME.17 Lacosa-
mide has also been used as an add-on treatment in a patient with
type 1 progressive myoclonic epilepsy, causing a signiﬁcant
reduction in the number of myoclonic events and improved
cognition.28 The ultimate mechanism responsible for ictal myo-
clonic jerks in JME is thought to be largely similar to cortical
myoclonus in progressive myoclonic epilepsies.29
Our three patients are quite representative of patients that are
routinely diagnosed with classic JME in everyday practice of
epilepsy. They all had normal cognition, and experienced juvenile
onset myoclonic jerks followed by convulsions, additionally one
patient experienced absence seizures. They all had normal MRI and
classical EEG features of JME. Our three patients were not
necessarily intractable. Two had a period of good seizure control
on VPA and/or LTG and one was not well controlled on these agents
(either as monotherapy or in combination). The patients were
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willing to try otherAEDs approved for treatment of JME (due to side
effect proﬁle). None of the patients experienced worsening of their
myoclonus, and in one patient intermittent myoclonic jerks
responded to increased dosage of lacosamide. In these three
patients, we did not observe any special pharmacodynamic actions
causing exacerbation or worsening of their JME.
In conclusion, due to a need for lifelong treatment, the choice of
AED in juvenile myoclonic epilepsy is of particular importance. The
acute idiosyncratic and chronic dose-related side effects of AEDs
can affect patients’ quality of life and morbidity, while inappro-
priately chosen AEDs can aggravate this syndrome and cause
pseudo-intractability. The data from our three patients suggest
that lacosamide does not necessarily aggravate JME, and in two of
the patients it may have been effective in the treatment of JME.
Larger studies are needed to further explore the efﬁcacy and role of
lacosamide in the treatment of this disorder.
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